Is Merck Stock a Bargain Buy?
Merck (NYSE: MRK) is a top healthcare company with one of the best drugs ever made in its portfolio: Keytruda. While there are concerns about its patent losses in the future, its sales are still growing. And the company has been working on ways to try and extend its growth into new areas. Plus, other drugs could generate billions more in the future.
Despite this potential, the stock has fallen by 25% in the past 12 months -- so is it a bargain buy right now?
During the last three months of 2024, Merck achieved solid 9% revenue growth (excluding the impact of foreign currency), with its top line hitting $15.6 billion. A big part of that was Keytruda, which brought in $7.8 billion on its own, as it achieved an organic growth rate of 21%. There has been an increase in demand for the drug, as it can help patients battle multiple types of cancers.
Source Fool.com
Merck KGaA Aktie
Merck KGaA sticht etwas positiv hervor mit 4 Buy- und 0 Sell-Einschätzungen.
Das durchschnittliche Community-Kursziel von 142 € für Merck KGaA impliziert eine Steigerung von über 20% gegenüber 118.15 €.
